Katherine Vega Stultz is a pharmaceutical industry veteran who currently leads the Project Leadership and Portfolio Management Team for the Hematology & Oncology Franchise at Celgene. She served as Project Leader for one of Celgene’s largest assets maximizing the lifecycle strategy inclusive of several new clinical programs and global approvals across multiple indications in over 60 countries. Her scope within the Project Leadership team grew as she took on projects not only affecting her assets, but also Celgene capabilities impacting operational excellence. Katherine was appointed to lead the Hematology & Oncology Project Leadership team in early 2016. In this capacity she is responsible for enabling overall long term portfolio decisions to optimize the development of the hematology & oncology portfolio. She serves as a senior member of the H/O Franchise Leadership Team, Portfolio Leadership Team and Development Committees. Katherine is also responsible for project reporting processes and leads the development of processes required to optimize the cross-functional development of assets across Celgene Franchises. Katherine has been at Celgene since 2005 growing in responsibilities from global strategic marketing, in line successes inclusive of the initial Revlimid launch in multiple myeloma. She has led a highly regarded reimbursement and patient access team as well as built organizations in sales and marketing. Prior to Celgene she was with Eli Lilly and ConvaTec spanning both commercial and development roles with more than half of her career being focused in oncology drug development. She has a Biomedical Engineering Degree from Cornell University and a Management Development Certificate from Darden. She is driven knowing her work impacts the lives of thousands of patients worldwide.